Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

AstraZeneca has used artificial intelligence to devise a unique biomarker for its Daiichi Sankyo-partnered datopotamab ...

AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

"We are honored to welcome Dave to Caris' Board of Directors," said David Dean ... Mr. Fredrickson is Executive Vice-President of the Oncology Business Unit at AstraZeneca PLC, a position he ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery ...

Tampa, Fla.-based Moffitt Cancer Center and drugmaker AstraZeneca are collaborating to accelerate the development of CAR-T cell and T cell receptor therapies. "We are excited to collaborate with ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.

We are honored to welcome Dave Frederickson to Caris' Board of Directors "We are honored to welcome Dave to Caris' Board of Directors," said David Dean Halbert, DSc (h.c.), Chairman, Founder and ...

"We are honored to welcome Dave to Caris' Board of Directors," said David Dean Halbert ... technologies to improve patient care." Mr. Fredrickson is Executive Vice-President of the Oncology Business ...